ST西发（000752）公告，公司2024年年度报告显示涉及的部分其他风险警示情形已消除，且不触及退 市风险警示。公司提交的撤销部分其他风险警示申请已获深圳证券交易所审核同意。但公司前期被实施 的其他风险警示情形尚未全部消除，股票简称和日涨跌幅限制不变。公司2024年归属于母公司股东的净 利润2619.63万元，扣除非经常性损益后净利润2741.49万元。 ...

Core Viewpoint - A listed company in Shenzhen faced a significant operational impact due to its subsidiary's non-compliance with GMP standards, leading to a production and sales suspension, which resulted in a stock price drop to the daily limit [1] Group 1: Company Impact - The subsidiary generated revenue of 216.57 million yuan and a net loss of 14.00 million yuan in 2024, accounting for 60.09% of the listed company's revenue and 9.8% of its consolidated net profit, indicating a substantial impact on the parent company's operations [1] - The company may face other risk warnings if the subsidiary's production does not resume within three months, as per the Shenzhen Stock Exchange's regulations [1] Group 2: Social Responsibility - Companies in the pharmaceutical sector must prioritize social responsibility and product safety, as the quality of drugs directly affects public health [2] - The concept of "pharmaceutical ethics" should guide the operations of pharmaceutical companies, balancing profit maximization with stakeholder interests [2] Group 3: Recommendations for Improvement - It is recommended that pharmaceutical companies innovate their internal governance by establishing independent quality control committees to oversee production processes and ensure compliance with GMP standards [2] - Companies should enhance their social responsibility disclosures, especially in cases of significant incidents or regulatory actions, to maintain transparency and accountability [3] - The trading rules should be revised to provide clearer criteria for implementing risk warnings, ensuring that the exchange, rather than the company, determines the necessity for such warnings [3] Group 4: Conclusion - Pharmaceutical companies must embed the principle of "quality is life" into their governance structures and operational practices to succeed in both capital markets and public health demands [4]